CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes

Rhea-AI Filing Summary

CRISPR Therapeutics CEO Samarth Kulkarni reported a mix of equity grants, vesting, and a small mandated share sale. On March 20, 2026, restricted stock units covering 19,687 Common Shares vested and were settled into shares, and he received a new stock option for 114,249 Common Shares at an exercise price of $46.24, plus a new restricted stock unit award for 81,875 Common Shares with vesting from 2027 through 2030.

On March 23, 2026, 10,020 Common Shares were sold at $46.78 per share solely to cover tax withholding tied to the RSU vesting, pursuant to the company’s RSU Settlement Policy and described as a non-discretionary transaction. After these events, Kulkarni held 255,501 Common Shares directly, and certain shares remain subject to a lock-up agreement related to the company’s convertible senior notes due 2031.

Insights

Equity compensation and governance analyst

Routine CEO equity awards with a small, mandated tax sale.

CRISPR Therapeutics’ CEO received sizeable equity compensation on March 20, 2026, including an option for 114,249 Common Shares at $46.24 and 81,875 new restricted stock units. Existing RSUs partially vested, delivering 19,687 Common Shares and increasing his direct share ownership.

Three days later, 10,020 Common Shares were sold at $46.78 per share. A footnote states this sale was required to cover tax withholding under the company’s RSU Settlement Policy, not a discretionary trade. The sale represents only a small portion of his 255,501 Common Shares held afterward.

Because the activity is primarily compensation-related and the disposition is tax-driven rather than a voluntary reduction of exposure, it appears as routine insider activity rather than a thesis-changing signal. Some of his shares remain subject to a lock-up tied to the company’s convertible senior notes due 2031, which may limit near-term flexibility to sell additional shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/20/2026		M(1)		19,687	A	(2)	265,521	D
Common Shares	03/23/2026		S		10,020(3)	D	$46.78	255,501	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.24	03/20/2026		A(1)		114,249		(4)	03/20/2036	Common Shares	114,249	$0.00	114,249	D
Restricted Stock Units	(5)	03/20/2026		A(1)		81,875		(5)	(5)	Common Shares	81,875	$0.00	81,875	D
Restricted Stock Units	(2)	03/20/2026		M(1)			19,687	(6)	(6)	Common Shares	19,687	(2)	39,375	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. This option was granted on March 20, 2026 with respect to 114,249 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.

5. This restricted stock unit award was granted on March 20, 2026 with respect to 81,875 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

6. This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CRISPR Therapeutics (CRSP) CEO receive in new equity awards?

The CEO received a stock option for 114,249 Common Shares at an exercise price of $46.24 and a new restricted stock unit award for 81,875 Common Shares, vesting annually from March 2027 through March 2030, strengthening his long-term equity-based compensation.

How many CRSP shares did the CEO sell in this Form 4 filing?

The CEO reported selling 10,020 Common Shares at $46.78 per share. A footnote explains this sale was solely to cover tax withholding obligations from restricted stock unit vesting, under the company’s RSU Settlement Policy, rather than a discretionary decision to reduce his holdings.

How many CRISPR Therapeutics shares does the CEO hold after these transactions?

Following the reported transactions, the CEO directly holds 255,501 Common Shares. This figure reflects the net result after RSU vesting, new share issuance from those RSUs, and the 10,020-share sale to satisfy associated tax withholding obligations described in the filing’s footnotes.

What are the vesting terms of the CEO’s new CRSP stock option grant?

The stock option for 114,249 Common Shares was granted on March 20, 2026. According to the footnote, 100% of the underlying shares will vest in 48 equal monthly installments, beginning on April 20, 2026, spreading vesting evenly over four years.

What are the vesting terms of the new CRISPR Therapeutics RSU award?

The new RSU award for 81,875 Common Shares was granted March 20, 2026. One quarter of the shares vest on each of March 20, 2027, March 20, 2028, March 20, 2029, and March 20, 2030, creating a four-year, time-based vesting schedule for the award.

Was the CRSP CEO’s share sale part of a trading plan or tax withholding?

The filing states the 10,020-share sale was mandated by the company’s RSU Settlement Policy to fund tax withholding tied to restricted stock unit vesting. The footnote clarifies it does not represent a discretionary trade, but a tax-driven transaction required by policy.

Are any of the CEO’s CRISPR Therapeutics shares subject to lock-up restrictions?

Yes. A footnote notes that certain shares remain subject to a lock-up agreement with the underwriters of CRISPR Therapeutics’ offering of convertible senior notes due 2031, which imposes restrictions on the timing or ability to sell those particular shares for a defined period.